Transcranial magnetic stimulation (TMS) therapy for autism: an international consensus conference held in conjunction with the international meeting for autism research on May 13th and 14th, 2014

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.3389/fnhum.2014.01034</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890712">http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890712</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Transcranial magnetic stimulation (TMS) therapy for autism: an international consensus conference held in conjunction with the international meeting for autism research on May 13th and 14th, 2014

Lindsay M. Oberman1*, Peter G. Enticott2, Manuel F. Casanova3, Alexander Rotenberg4,5, Alvaro Pascual-Leone4,5 and James T. McCracken6

1 Neuropsychiatry and Autism Spectrum Disorder Program, Department of Psychiatry and Human Behavior, E.P. Bradley Hospital and Warren Alpert Medical School, Brown University, Providence, RI, USA
2 Cognitive Neuroscience Unit, School of Psychology, Deakin University, Burwood, VIC, Australia
3 Department of Psychiatry and Behavioral Science, University of Louisville, Louisville, KY, USA
4 Neuromodulation Program, Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA
5 Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
6 Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA

*Correspondence: loberman@lifespan.org

THE CENTERs FOR DISEASE CONTROL AND PREVENTION CURRENTLY ESTIMATE THE PREVALENCE OF AUTISM SPECTRUM DISORDER (ASD) IN THE U.S. AT 1:68 CHILDREN (Baio, 2014). Despite decades of research across multiple levels of analysis, we currently lack a reliable biomarker that may facilitate diagnosis, illuminate pathophysiology, or guide treatment. The development of novel treatment strategies for ASD will require efforts for better clinical characterization, identification of more homogeneous subgroups for studies, and improved understanding of underlying pathophysiology. There is growing support for early intensive interventions in this population (Reichow, 2012). Pharmacological treatments have been shown to be effective in treating some of the common secondary and comorbid features of ASD (Hampson et al., 2012), but there is currently no pharmacotherapy conclusively shown to improve the core symptoms (Oberman, 2012).

Recently a number of investigators have begun to explore the use of transcranial magnetic stimulation (TMS) as a tool to characterize ASD pathophysiology, and to test its therapeutic potential. TMS is a safe and well-tolerated method for non-invasive focal cortical stimulation where small intracranial electrical currents are generated by a rapidly fluctuating extracranial magnetic field. In an effort to share recent progress in the use of TMS in ASD, promote collaboration across laboratories, and establish consensus on parameters that may be useful for the study of pathophysiology and the potential treatment of ASD, leading experts in the field gathered in Atlanta, GA on May 13th and 14th 2014 for the “Transcranial Magnetic Stimulation Therapy for Autism Consensus Conference” organized and supported by the Clearly for Autism Consensus Conference organized and supported by the Clearly

Edited by:
Rachael D. Seidler, University of Michigan, USA

Reviewed by:
Jorge Leon Morales-Quezada, Laboratory of Neuromodulation, USA

Keywords: Autism Spectrum Disorder, transcranial magnetic stimulation, pathophysiology, therapy, consensus

The Centers for Disease Control and Prevention currently estimate the prevalence of Autism Spectrum Disorder (ASD) in the U.S. at 1:68 children (Baio, 2014). Despite decades of research across multiple levels of analysis, we currently lack a reliable biomarker that may facilitate diagnosis, illuminate pathophysiology, or guide treatment. The development of novel treatment strategies for ASD will require efforts for better clinical characterization, identification of more homogeneous subgroups for studies, and improved understanding of underlying pathophysiology. There is growing support for early intensive interventions in this population (Reichow, 2012). Pharmacological treatments have been shown to be effective in treating some of the common secondary and comorbid features of ASD (Hampson et al., 2012), but there is currently no pharmacotherapy conclusively shown to improve the core symptoms (Oberman, 2012).

Recently a number of investigators have begun to explore the use of transcranial magnetic stimulation (TMS) as a tool to characterize ASD pathophysiology, and to test its therapeutic potential. TMS is a safe and well-tolerated method for non-invasive focal cortical stimulation where small intracranial electrical currents are generated by a rapidly fluctuating extracranial magnetic field. In an effort to share recent progress in the use of TMS in ASD, promote collaboration across laboratories, and establish consensus on parameters that may be useful for the study of pathophysiology and the potential treatment of ASD, leading experts in the field gathered in Atlanta, GA on May 13th and 14th 2014 for the “Transcranial Magnetic Stimulation Therapy for Autism Consensus Conference” organized and supported by the Clearly

Edited by:
Rachael D. Seidler, University of Michigan, USA

Reviewed by:
Jorge Leon Morales-Quezada, Laboratory of Neuromodulation, USA

Keywords: Autism Spectrum Disorder, transcranial magnetic stimulation, pathophysiology, therapy, consensus

The Centers for Disease Control and Prevention currently estimate the prevalence of Autism Spectrum Disorder (ASD) in the U.S. at 1:68 children (Baio, 2014). Despite decades of research across multiple levels of analysis, we currently lack a reliable biomarker that may facilitate diagnosis, illuminate pathophysiology, or guide treatment. The development of novel treatment strategies for ASD will require efforts for better clinical characterization, identification of more homogeneous subgroups for studies, and improved understanding of underlying pathophysiology. There is growing support for early intensive interventions in this population (Reichow, 2012). Pharmacological treatments have been shown to be effective in treating some of the common secondary and comorbid features of ASD (Hampson et al., 2012), but there is currently no pharmacotherapy conclusively shown to improve the core symptoms (Oberman, 2012).

Recently a number of investigators have begun to explore the use of transcranial magnetic stimulation (TMS) as a tool to characterize ASD pathophysiology, and to test its therapeutic potential. TMS is a safe and well-tolerated method for non-invasive focal cortical stimulation where small intracranial electrical currents are generated by a rapidly fluctuating extracranial magnetic field. In an effort to share recent progress in the use of TMS in ASD, promote collaboration across laboratories, and establish consensus on parameters that may be useful for the study of pathophysiology and the potential treatment of ASD, leading experts in the field gathered in Atlanta, GA on May 13th and 14th 2014 for the “Transcranial Magnetic Stimulation Therapy for Autism Consensus Conference” organized and supported by the Clearly

Edited by:
Rachael D. Seidler, University of Michigan, USA

Reviewed by:
Jorge Leon Morales-Quezada, Laboratory of Neuromodulation, USA

Keywords: Autism Spectrum Disorder, transcranial magnetic stimulation, pathophysiology, therapy, consensus

The Centers for Disease Control and Prevention currently estimate the prevalence of Autism Spectrum Disorder (ASD) in the U.S. at 1:68 children (Baio, 2014). Despite decades of research across multiple levels of analysis, we currently lack a reliable biomarker that may facilitate diagnosis, illuminate pathophysiology, or guide treatment. The development of novel treatment strategies for ASD will require efforts for better clinical characterization, identification of more homogeneous subgroups for studies, and improved understanding of underlying pathophysiology. There is growing support for early intensive interventions in this population (Reichow, 2012). Pharmacological treatments have been shown to be effective in treating some of the common secondary and comorbid features of ASD (Hampson et al., 2012), but there is currently no pharmacotherapy conclusively shown to improve the core symptoms (Oberman, 2012).

Recently a number of investigators have begun to explore the use of transcranial magnetic stimulation (TMS) as a tool to characterize ASD pathophysiology, and to test its therapeutic potential. TMS is a safe and well-tolerated method for non-invasive focal cortical stimulation where small intracranial electrical currents are generated by a rapidly fluctuating extracranial magnetic field. In an effort to share recent progress in the use of TMS in ASD, promote collaboration across laboratories, and establish consensus on parameters that may be useful for the study of pathophysiology and the potential treatment of ASD, leading experts in the field gathered in Atlanta, GA on May 13th and 14th 2014 for the “Transcranial Magnetic Stimulation Therapy for Autism Consensus Conference” organized and supported by the Clearly

Edited by:
Rachael D. Seidler, University of Michigan, USA

Reviewed by:
Jorge Leon Morales-Quezada, Laboratory of Neuromodulation, USA

Keywords: Autism Spectrum Disorder, transcranial magnetic stimulation, pathophysiology, therapy, consensus

The Centers for Disease Control and Prevention currently estimate the prevalence of Autism Spectrum Disorder (ASD) in the U.S. at 1:68 children (Baio, 2014). Despite decades of research across multiple levels of analysis, we currently lack a reliable biomarker that may facilitate diagnosis, illuminate pathophysiology, or guide treatment. The development of novel treatment strategies for ASD will require efforts for better clinical characterization, identification of more homogeneous subgroups for studies, and improved understanding of underlying pathophysiology. There is growing support for early intensive interventions in this population (Reichow, 2012). Pharmacological treatments have been shown to be effective in treating some of the common secondary and comorbid features of ASD (Hampson et al., 2012), but there is currently no pharmacotherapy conclusively shown to improve the core symptoms (Oberman, 2012).
et al., 2013). Morphometric analysis of cells within the malformed cortex has suggested a reduced number of interneurons (Casanova et al., 2013). This is consistent with previous reports of abnormalities in ASD within the peripheral cortical minicolumn neuropil space, the compartment where most inhibitory cells are located (Casanova et al., 2002). Both EEG and vibrotactile studies corroborate a deficit of cortical lateral inhibition (Keita et al., 2011; Puts et al., 2014). He proposed that this deficit could account for the seizures and sensory abnormalities often reported in ASD.

Lindsay Oberman discussed the use of TMS as an investigative device to study cortical excitability and plasticity in ASD. These studies show that a number of basic mechanisms and circuits are atypical while other measures appear to be normal (see Oberman et al., 2013). Specifically, motor thresholds and baseline motor-cortical excitability measures appear to be normal. There is heterogeneity in the response to paired-pulse paradigms with impaired inhibition in some individuals, typical response in others, and paradoxical facilitation in another subgroup. Studies exploring corticospinal plasticity mechanisms, using two different rTMS protocols [theta burst stimulation (TBS) and paired associative stimulation (PAS)], have shown abnormalities. However, the direction of the abnormality is unclear with TBS studies showing enhanced response (Oberman et al., 2012) and PAS showing reduced response (Jung et al., 2013). There are a number of open questions related to the use of TMS as an investigative device in ASD including developmental effects, effects related to intellectual disability and functioning, and what underlying mechanisms are driving the observed heterogeneity in the population.

Peter Enticott discussed the efficacy of rTMS as a therapeutic intervention in ASD. A number of studies using low-frequency rTMS in an effort to enhance cortical inhibitory tone in dorsalateral prefrontal cortex have resulted in improvements in EEG indices of attention, information processing, and error monitoring as well as behavioral improvements in repetitive behaviors and irritability (Sokhadze et al., 2014). Low-frequency stimulation to left pars triangularis resulted in improved object naming in a single session study (Fecteau et al., 2011). High-frequency stimulation, designed to enhance excitability, has suggested improvements in self-reported social relating and social anxiety following medial prefrontal cortex stimulation (Enticott et al., 2014) and significant improvements in eye-hand coordination following premotor stimulation (Paneri et al., 2013). Although an emerging literature, these studies collectively provide support for the potential efficacy of rTMS in ASD (Oberman et al., 2013). However, the small study samples, lack of blind assessments, and limited use of control or comparison conditions limit the interpretation of these early investigations.

James McCracken concluded the conference by discussing key factors to consider when designing clinical trials for ASD. These factors included identification of valid and reliable endpoints, incorporation of blind assessments, need for credible control conditions, establishment of effective stimulation parameters, need to relate changes in electrophysiological endpoints to functional change, and identification of biomarkers that can be used to reduce the heterogeneity of the sample and stratify participants to treatment strategies that are best matched to their underlying pathophysiology. To this end, those present discussed the utility of developing functional imaging and TMS indices as potential standardized biomarkers and the need for larger, multisite trials to establish validity of these measures across development and levels of functioning and reliability of these measures across centers.

At the conclusion of the conference, there was enthusiasm for the potential use of TMS in ASD. Further work is necessary to achieve consensus on the key factors discussed by Dr. McCracken, but the expertise and commitment is present in the research and clinical community to work toward the end goal of designing and implementing large-scale, double blind, multisite clinical trials of rTMS for ASD in the near future. Those present committed to collaborate across laboratories to establish mutually agreed upon protocols and to meet again within 1 year.

**AUTHOR CONTRIBUTIONS**

Lindsay M. Oberman, Peter G. Enticott, Manuel F. Casanova, Alvaro Pascual-Leone, and James T. McCracken contributed to the organization of the conference, were invited speakers to the conference, and lead the discussion during the conference. Alexander Rotenberg contributed to the organization of the conference, and the discussion during the conference. All authors contributed to the writing of the manuscript.

**ACKNOWLEDGMENT**

The content is solely the responsibility of the authors and does not necessarily represent the official views of Clearly Present Foundation, Autism Speaks, or Neurotensin, Inc.

**REFERENCES**


**Conflict of Interest Statement:** Alvaro Pascual-Leone serves on the scientific advisory boards for Nexstim, Neuronix, Starlab Neuroscience, Axilum Robotics, Magstim, Neuroelectronics, and Neosync; and is listed as an inventor on several issued and pending patents on the real-time integration of transcranial magnetic stimulation (TMS) with electroencephalography (EEG) and magnetic resonance imaging (MRI). Alexander Rotenberg is listed as an inventor on a patent for apparatus and method of use of TMS in epilepsy. He is a co-founder of Neuromotion Inc. This conference was supported by the Clearly Present Foundation, Autism Speaks, and Neuronetics, Inc. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 12 November 2014; accepted: 09 December 2014; published online: 06 January 2015.


This article was submitted to the journal Frontiers in Human Neuroscience.

Copyright © 2015 Oberman, Enticott, Casanova, Rotenberg, Pascual-Leone and McCracken. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.